SPONSOR
Western Sydney Local Health District
Total Trials
2
Recruiting
2
Phases
Phase 2
Western Sydney Local Health District is a clinical research sponsor with 2 registered studies on ClinicalTrials.gov, of which 2 are actively recruiting participants. Research covers conditions including Huntington Disease, Sudden Cardiac Death.
The trial portfolio spans Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Western Sydney Local Health District
How many clinical trials has Western Sydney Local Health District sponsored?
ClinicalMetric currently tracks 2 clinical trials sponsored by Western Sydney Local Health District, of which 2 are actively recruiting participants. These trials cover conditions including Huntington Disease, Sudden Cardiac Death. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Western Sydney Local Health District research focus on?
Western Sydney Local Health District clinical trials span Huntington Disease, Sudden Cardiac Death. The research pipeline includes Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Western Sydney Local Health District clinical trial?
To participate in a Western Sydney Local Health District trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Western Sydney Local Health District trials with current recruitment status updated daily.
Clinical Trials by Western Sydney Local Health District
NCT05509153 Phase 2
Recruiting
A Randomised Controlled Trial, Of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers
Huntington Disease
NCT03588286
Recruiting
Programmed Ventricular Stimulation to Risk Stratify for Early Cardioverter-Defibrillator (ICD) Implantation to Prevent Tachyarrhythmias Following Acute Myocardial Infarction (PROTECT-ICD)
Sudden Cardiac Death
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology